Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Essential Therapeutics (ETRX) formerly Microcide (MCDE -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (181)	2/5/1999 11:25:00 PM
From: John Dwyer	Read Replies (1) \| Respond to of 415

Hi all, Still long on MCDE although progress has been painfully slow. We'll see how 1999 goes... I don't think the MLNM patent will have an impact on MCDE. I would have to read the language of the claims but as far as I understand, MCDE uses pretty standard functional genomics to isolate essential genes. Beyond that (screening, etc) it is proprietary but it appears the MLNM patent concerns identification of the genes. The VITA program at Cubist sounds more like the type of thing MLNM is after. They have filed patents for the genomics and screening technology and some of this might overlap MLNM's patent. A patent battle could emerge which could be potentially bad for CBST. However, the genes are what are important to MCDE's platform. If worse comes to worse, MCDE could simply license the technology from MLNM and it would likely be a non-issue. I can't see MCDE starting a big patent battle over this... John